| scholarly article | Q13442814 |
| P2093 | author name string | David Kavanagh | |
| Vicky Brocklebank | |||
| P2860 | cites work | Complement 5a receptor mediates angiotensin II-induced cardiac inflammation and remodeling | Q87704151 |
| Recovery from life-threatening transplantation-associated thrombotic microangiopathy using eculizumab in a patient with very severe aplastic anemia | Q87858624 | ||
| Efficacy of a rituximab regimen based on B cell depletion in thrombotic thrombocytopenic purpura with suboptimal response to standard treatment: Results of a phase II, multicenter noncomparative study | Q88359679 | ||
| Gemcitabine-Associated Thrombotic Microangiopathy: Response to Complement Inhibition and Reinitiation of Gemcitabine | Q88558179 | ||
| Late onset of de novo atypical hemolytic-uremic syndrome presented on a simultaneous pancreas and kidney transplant recipient successfully treated with eculizumab | Q89057263 | ||
| Patients with hypertension-associated thrombotic microangiopathy may present with complement abnormalities | Q89253068 | ||
| Prevention of recurrence of atypical hemolytic uremic syndrome post renal transplant with the use of higher-dose eculizumab | Q95526876 | ||
| Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II) | Q24317382 | ||
| Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome | Q24337607 | ||
| Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype | Q24613907 | ||
| Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis | Q24615589 | ||
| Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome | Q24622189 | ||
| Eculizumab for dense deposit disease and C3 glomerulonephritis | Q24632330 | ||
| VEGF inhibition and renal thrombotic microangiopathy | Q24632792 | ||
| Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome | Q24634697 | ||
| Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome | Q24653523 | ||
| Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome | Q24685473 | ||
| Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature | Q26864297 | ||
| Structural basis for sialic acid-mediated self-recognition by complement factor H | Q27696183 | ||
| Eculizumab in severe Shiga-toxin-associated HUS | Q28238525 | ||
| Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis | Q28239591 | ||
| Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome | Q28243693 | ||
| Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab | Q28260452 | ||
| Eculizumab in a patient with dense-deposit disease | Q28262415 | ||
| The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection | Q28299356 | ||
| Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort | Q28741729 | ||
| Eculizumab for the Treatment of Dense-Deposit Disease | Q29308023 | ||
| Eculizumab and Refractory Membranoproliferative Glomerulonephritis | Q29395322 | ||
| Complement: a key system for immune surveillance and homeostasis | Q29615484 | ||
| Insights into kidney diseases from genome-wide association studies | Q30248678 | ||
| Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue | Q30276550 | ||
| The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome. | Q30377280 | ||
| Acute renal failure in the course of HIV infection: a single-institution retrospective study of ninety-two patients and sixty renal biopsies | Q33329310 | ||
| Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura | Q33332517 | ||
| The association of pregnancy with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome | Q33349468 | ||
| Systemic lupus erythematosus and thrombotic thrombocytopenic purpura: a case report and literature review. | Q33357305 | ||
| Thrombotic microangiopathy after renal transplantation in the United States | Q33357327 | ||
| Familial mesangio-capillary glomerulonephritis with initial presentation as haemolytic uraemic syndrome | Q33358128 | ||
| Thrombotic Microangiopathies | Q56286857 | ||
| Atypical hemolytic uremic syndrome | Q56591965 | ||
| Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies | Q56908029 | ||
| Complement Mutation-AssociatedDe NovoThrombotic Microangiopathy Following Kidney Transplantation | Q56965937 | ||
| A Randomized, Controlled Trial of Steroids and Cyclophosphamide in Adults with Nephrotic Syndrome Caused by Idiopathic Membranous Nephropathy | Q57371622 | ||
| Eculizumab for Atypical Hemolytic–Uremic Syndrome | Q57636966 | ||
| Eculizumab and Splenectomy as Salvage Therapy for Severe Antibody-Mediated Rejection After HLA–Incompatible Kidney Transplantation | Q58048136 | ||
| Eculizumab Prevents Recurrent Antiphospholipid Antibody Syndrome and Enables Successful Renal Transplantation | Q58048140 | ||
| Eculizumab in dense-deposit disease after renal transplantation | Q59273614 | ||
| Eculizumab treatment for rescue of renal function in IgA nephropathy | Q61408066 | ||
| A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice | Q61415573 | ||
| Prognosis of scleroderma renal crisis: a long-term observational study | Q61649506 | ||
| A case of C3 glomerulonephritis successfully treated with eculizumab | Q63564996 | ||
| Rituximab fails where eculizumab restores renal function in C3nef-related DDD | Q64050925 | ||
| Pathogenesis of Thrombotic Microangiopathy: Insights from Animal Models | Q64449260 | ||
| Haemolytic uraemic syndrome and idiopathic membranous glomerulonephritis | Q67315892 | ||
| Recurrent haemolytic uraemic syndrome in a boy with focal and segmental glomerulosclerosis | Q67575517 | ||
| Enhanced anaphylatoxin and terminal C5b-9 complement complex formation in patients with the syndrome of hemolysis, elevated liver enzymes, and low platelet count | Q68565309 | ||
| Glomerular deposition of mannose-binding lectin (MBL) indicates a novel mechanism of complement activation in IgA nephropathy | Q77156489 | ||
| Deposition of mannan binding protein and mannan binding protein-mediated complement activation in the glomeruli of patients with IgA nephropathy | Q77614997 | ||
| Light at the end of the TUNEL: HIV-associated thrombotic microangiopathy | Q78630797 | ||
| Renal biopsy findings predicting outcome in scleroderma renal crisis | Q79761928 | ||
| Successful treatment of thrombotic microangiopathy after haematopoietic stem cell transplantation with rituximab | Q80155799 | ||
| ABO-incompatible allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning: close association with transplant-associated microangiopathy | Q80479511 | ||
| Glomerular deposition and urinary excretion of complement factor H in idiopathic membranous nephropathy | Q80497195 | ||
| The renin-angiotensin system in malignant hypertension revisited: plasma renin activity, microangiopathic hemolysis, and renal failure in malignant hypertension | Q80748271 | ||
| Rituximab for allo-SCT-associated thrombotic thrombocytopenic purpura | Q80813563 | ||
| Thrombotic microangiopathy following pancreas after kidney transplants | Q80867515 | ||
| Complement activation in patients with primary antiphospholipid syndrome | Q81638094 | ||
| Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome | Q81703928 | ||
| Activation of the complement system in normal pregnancy and preeclampsia | Q83021096 | ||
| Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies | Q83203130 | ||
| Is complement factor H a susceptibility factor for IgA nephropathy? | Q83223359 | ||
| Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease | Q83316223 | ||
| Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura | Q83625618 | ||
| Eculizumab for the treatment of two recurrences of atypical hemolytic uremic syndrome in a kidney allograft | Q84145395 | ||
| Prompt reversal of a severe complement activation by eculizumab in a patient undergoing intentional ABO-incompatible pancreas and kidney transplantation | Q84420087 | ||
| Human serum complement C3 and factor H in the syndrome of hemolysis, elevated liver enzymes, and low platelet count | Q84457224 | ||
| Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome | Q84581798 | ||
| Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients | Q84977614 | ||
| Successful treatment of de novo posttransplant thrombotic microangiopathy with eculizumab | Q85075727 | ||
| Patient stratification and therapy in atypical haemolytic uraemic syndrome (aHUS) | Q85282478 | ||
| Case report: Eculizumab rescue of severe accelerated antibody-mediated rejection after ABO-incompatible kidney transplant | Q85570146 | ||
| Eculizumab for treatment of rapidly progressive C3 glomerulopathy | Q86369588 | ||
| Eculizumab to treat antibody-mediated rejection in a 7-year-old kidney transplant recipient | Q86605327 | ||
| Liver-kidney transplantation to cure atypical HUS: still an option post-eculizumab? | Q86992827 | ||
| Eculizumab therapy in a patient with dense-deposit disease associated with partial lipodystropy | Q87166523 | ||
| A case of thrombotic microangiopathy associated with antiphospholipid antibody syndrome successfully treated with eculizumab | Q87495399 | ||
| Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy: A Study From the SFGM-TC. | Q33420170 | ||
| Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies | Q33420172 | ||
| Hematopoietic transplant-associated thrombotic microangiopathy: case report and review of diagnosis and treatments | Q33420187 | ||
| Activation of the alternative pathway of complement during the acute phase of typical haemolytic uraemic syndrome. | Q33420374 | ||
| Complement, thrombotic microangiopathy and disseminated intravascular coagulation | Q33420624 | ||
| Hematopoietic stem cell transplantation-associated thrombotic microangiopathy accompanied by renal arteriolar C4d deposition | Q33420858 | ||
| Clinicopathologic characteristics and outcomes of renal thrombotic microangiopathy in anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis | Q33420968 | ||
| Atypical aHUS: State of the art. | Q33421720 | ||
| Characterization of a New DGKE Intronic Mutation in Genetically Unsolved Cases of Familial Atypical Hemolytic Uremic Syndrome | Q33421800 | ||
| A phase-II sequential case-series study of all patients presenting to four plasma exchange centres with presumed relapsed/refractory thrombotic thrombocytopenic purpura treated with rituximab | Q33421822 | ||
| An international consensus approach to the management of atypical hemolytic uremic syndrome in children | Q33421861 | ||
| Cytomegalovirus-induced thrombotic microangiopathy after renal transplant successfully treated with eculizumab: case report and review of the literature | Q33421909 | ||
| A national specialized service in England for atypical haemolytic uraemic syndrome-the first year's experience | Q33422224 | ||
| Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases | Q33422371 | ||
| Case report: Benefits and challenges of long-term eculizumab in atypical hemolytic uremic syndrome | Q33422540 | ||
| Thrombotic microangiopathy, cancer, and cancer drugs | Q33422553 | ||
| Rescue therapy with eculizumab in a transplant recipient with atypical haemolytic-uraemic syndrome | Q33423593 | ||
| Eculizumab in Typical Hemolytic Uremic Syndrome (HUS) With Neurological Involvement | Q33423769 | ||
| Differentiating malignant hypertension-induced thrombotic microangiopathy from thrombotic thrombocytopenic purpura. | Q33424106 | ||
| Thrombotic microangiopathy and poor renal outcome in lupus patients with or without antiphospholipid syndrome. | Q33424696 | ||
| Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy | Q33424902 | ||
| Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort | Q33424946 | ||
| Thrombotic Microangiopathy as a Cause of Chronic Kidney Transplant Dysfunction: Case Report Demonstrating Successful Treatment with Eculizumab | Q33425766 | ||
| CFH gene mutation in a case of Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS). | Q33426147 | ||
| Treatment of Congenital Thrombotic Thrombocytopenic Purpura With Eculizumab | Q33426242 | ||
| A De Novo Deletion in the Regulators of Complement Activation Cluster Producing a Hybrid Complement Factor H/Complement Factor H-Related 3 Gene in Atypical Hemolytic Uremic Syndrome. | Q33426927 | ||
| Association of Serum C3 Concentration and Histologic Signs of Thrombotic Microangiopathy with Outcomes among Patients with ANCA-Associated Renal Vasculitis | Q33427362 | ||
| The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy | Q33427838 | ||
| Eculizumab for rescue of thrombotic microangiopathy in PM-Scl antibody-positive autoimmune overlap syndrome | Q33427917 | ||
| Eculizumab-related progressive multifocal leukoencephalopathy | Q33428818 | ||
| Genetic variations in complement factors in patients with congenital thrombotic thrombocytopenic purpura with renal insufficiency | Q33429667 | ||
| Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura | Q33429907 | ||
| Eculizumab in children with hemolytic uremic syndrome | Q33430031 | ||
| The role of complement in Streptococcus pneumoniae-associated haemolytic uraemic syndrome | Q33408549 | ||
| Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy | Q33408788 | ||
| Complement activation associated with ADAMTS13 deficiency in human and murine thrombotic microangiopathy | Q33409285 | ||
| Eculizumab for atypical hemolytic uremic syndrome in pregnancy | Q33409337 | ||
| Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation. | Q33409714 | ||
| Eculizumab long-term therapy for pediatric renal transplant in aHUS with CFH/CFHR1 hybrid gene | Q33410033 | ||
| Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation | Q33410621 | ||
| Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children | Q33410689 | ||
| Use of belatacept as alternative immunosuppression in three renal transplant patients with de novo drug-induced thrombotic microangiopathy | Q33411321 | ||
| Interaction of Shiga toxin 2 with complement regulators of the factor H protein family | Q33411951 | ||
| Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. | Q33412325 | ||
| Complement and cytokine response in acute Thrombotic Thrombocytopenic Purpura | Q33412347 | ||
| Eculizumab for drug-induced de novo posttransplantation thrombotic microangiopathy: A case report | Q33413137 | ||
| Phenotypic expansion of DGKE-associated diseases | Q33413254 | ||
| Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement | Q33413591 | ||
| Thrombotic microangiopathy associated with interferon beta | Q33414217 | ||
| Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts | Q33415390 | ||
| Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes | Q33415502 | ||
| Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults | Q33415603 | ||
| Prophylactic eculizumab for kidney transplantation in a child with atypical hemolytic uremic syndrome due to complement factor H mutation | Q33415937 | ||
| Atypical hemolytic uremic syndrome recurrence after kidney transplantation | Q33415949 | ||
| Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry | Q33416142 | ||
| Syndromes of thrombotic microangiopathy | Q33417044 | ||
| Complement mutations in diacylglycerol kinase-ε-associated atypical hemolytic uremic syndrome | Q33417173 | ||
| De novo thrombotic microangiopathy after non-renal solid organ transplantation | Q33417893 | ||
| 36-year-old female with catastrophic antiphospholipid syndrome treated with eculizumab: a case report and review of literature. | Q33418663 | ||
| Drug-induced thrombotic microangiopathy: a systematic review of published reports | Q33418784 | ||
| Eculizumab hepatotoxicity in pediatric aHUS. | Q33418797 | ||
| Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab | Q33419007 | ||
| Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome | Q33419128 | ||
| Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report. | Q33419171 | ||
| De novo tacrolimus-induced thrombotic microangiopathy in the early stage after renal transplantation successfully treated with conversion to everolimus | Q33419720 | ||
| Podocyte dysfunction in atypical haemolytic uraemic syndrome | Q33419853 | ||
| Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome | Q33420087 | ||
| Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy. | Q51059202 | ||
| Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. | Q51252547 | ||
| Antibody mediated rejection associated with complement factor h-related protein 3/1 deficiency successfully treated with eculizumab. | Q51333222 | ||
| Expression of the complement system's activation factors in plasma of patients with early/late-onset severe pre-eclampsia. | Q51614096 | ||
| Antagonist of C5aR prevents cardiac remodeling in angiotensin II-induced hypertension. | Q51758882 | ||
| Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy. | Q52875784 | ||
| Discontinuation of dialysis with eculizumab therapy in a pediatric patient with dense deposit disease. | Q53211895 | ||
| Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1 year. | Q53591741 | ||
| In vivo binding of complement regulator factor H by Streptococcus pneumoniae. | Q54632702 | ||
| Eculizumab for congenital atypical hemolytic-uremic syndrome. | Q55051403 | ||
| Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation. | Q55052808 | ||
| Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. | Q55052886 | ||
| Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. | Q55067043 | ||
| Inhibition of the mTORC pathway in the antiphospholipid syndrome. | Q55072769 | ||
| Pre-eclampsia | Q56019568 | ||
| Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement | Q35228543 | ||
| Conditioning for hematopoietic transplantation activates the complement cascade and induces a proteolytic environment in bone marrow: a novel role for bioactive lipids and soluble C5b-C9 as homing factors | Q35403165 | ||
| Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies | Q35570402 | ||
| Eculizumab and recurrent C3 glomerulonephritis | Q35597310 | ||
| Eculizumab and drug-induced haemolytic-uraemic syndrome | Q35626530 | ||
| Complement Activation in Patients with Focal Segmental Glomerulosclerosis | Q35763276 | ||
| Antigen-presenting cell-derived complement modulates graft-versus-host disease | Q36005386 | ||
| A hybrid CFHR3-1 gene causes familial C3 glomerulopathy. | Q36050943 | ||
| Cellular response to injury in membranous nephropathy | Q36084457 | ||
| Eculizumab in Pediatric Dense Deposit Disease | Q36123605 | ||
| DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN | Q36638388 | ||
| Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. | Q37410508 | ||
| Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature. | Q37508060 | ||
| Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review | Q37522227 | ||
| C5a receptor (CD88) blockade protects against MPO-ANCA GN | Q37524080 | ||
| Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome | Q37547496 | ||
| Complement activation and effect of eculizumab in scleroderma renal crisis. | Q37605730 | ||
| Severe renal failure and microangiopathic hemolysis induced by malignant hypertension--case series and review of literature. | Q37686597 | ||
| The role of complement in antibody-mediated rejection in kidney transplantation | Q38048605 | ||
| Targeting the complement system in systemic lupus erythematosus and other diseases | Q38102374 | ||
| The role of complement in membranous nephropathy | Q38155652 | ||
| Antibody-mediated rejection despite inhibition of terminal complement. | Q38427447 | ||
| Eculizumab for Treatment of Refractory Antibody-Mediated Rejection in Kidney Transplant Patients: A Single-Center Experience | Q38570448 | ||
| Complement, a target for therapy in inflammatory and degenerative diseases. | Q38614302 | ||
| The Revised (2013) Banff Classification for Antibody-Mediated Rejection of Renal Allografts: Update, Difficulties, and Future Considerations | Q38676925 | ||
| Recent Developments in the Classification, Evaluation, Pathophysiology, and Management of Scleroderma Renal Crisis | Q38681754 | ||
| Is complement blockade an acceptable therapeutic strategy for hematopoietic cell transplant-associated thrombotic microangiopathy? | Q38806679 | ||
| Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future | Q38848297 | ||
| Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis | Q38852573 | ||
| Renal thrombotic microangiopathy in patients with cblC defect: review of an under-recognized entity | Q38862309 | ||
| Eculizumab for the Treatment of Severe Antibody-Mediated Rejection: A Case Report and Review of the Literature. | Q38914719 | ||
| Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of 500 patients from the International CAPS Registry | Q38957667 | ||
| Scleroderma renal crisis and renal involvement in systemic sclerosis | Q38957950 | ||
| HIV-associated thrombotic microangiopathy in the era of highly active antiretroviral therapy: an observational study | Q33363316 | ||
| Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome | Q33364092 | ||
| Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases | Q33364209 | ||
| Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies | Q33365192 | ||
| Late-onset thrombocytic microangiopathy caused by cblC disease: association with a factor H mutation | Q33365284 | ||
| Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement | Q33365625 | ||
| Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation | Q33367451 | ||
| Hemolytic uremic syndrome after bone marrow transplantation: clinical characteristics and outcome in children | Q33369177 | ||
| Calcineurin inhibitor-free immunosuppression in renal allograft recipients with thrombotic microangiopathy/hemolytic uremic syndrome. | Q33369997 | ||
| Thrombotic microangiopathy after kidney transplantation | Q33372586 | ||
| Atypical haemolytic uraemic syndrome | Q33372627 | ||
| A clinicopathologic study of thrombotic microangiopathy in the setting of IgA nephropathy. | Q33373637 | ||
| Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic purpura: A report of 10 patients and a systematic review of published cases | Q33373876 | ||
| Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome | Q33375712 | ||
| Hemolytic uremic syndrome associated with invasive pneumococcal disease: the United kingdom experience | Q33375954 | ||
| Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background | Q33376237 | ||
| Complement factor H deficiency and posttransplantation glomerulonephritis with isolated C3 deposits | Q33379098 | ||
| Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials | Q33381765 | ||
| Membranous nephropathy and thrombotic thrombocytopenic purpura treated with rituximab. | Q33385705 | ||
| Cancer awareness in atypical thrombotic microangiopathies | Q33385833 | ||
| Is therapeutic plasma exchange indicated for patients with gemcitabine-induced hemolytic uremic syndrome? | Q33386556 | ||
| Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation | Q33386778 | ||
| Ten years of pneumococcal-associated haemolytic uraemic syndrome in New Zealand children | Q33386827 | ||
| Recurrent thrombotic thrombocytopenic purpura associated with membranous glomerulopathy | Q33386836 | ||
| Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations | Q33388474 | ||
| De novo thrombotic microangiopathy in renal allograft biopsies-role of antibody-mediated rejection | Q33390970 | ||
| Transplantation in atypical hemolytic uremic syndrome | Q33392013 | ||
| Clinical features of malignant hypertension with thrombotic microangiopathy. | Q33393559 | ||
| Escherichia coli Shiga Toxin Mechanisms of Action in Renal Disease | Q33394010 | ||
| Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome | Q33394691 | ||
| Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome | Q33395251 | ||
| A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura | Q33395642 | ||
| Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreas-kidney transplantation--a case report | Q33395870 | ||
| Viral-associated thrombotic microangiopathies. | Q33396084 | ||
| Streptococcus pneumoniae-associated hemolytic uremic syndrome among children in North America | Q33396296 | ||
| Invasive pneumococcal pneumonia is the major cause of paediatric haemolytic-uraemic syndrome in Taiwan | Q33396309 | ||
| Thrombotic microangiopathy mimicking membranoproliferative glomerulonephritis. | Q33396467 | ||
| Three kidneys, two diseases, one antibody? | Q33396530 | ||
| Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation | Q33396637 | ||
| Is complement a culprit in infection-induced forms of haemolytic uraemic syndrome? | Q33396771 | ||
| Renal thrombotic microangiopathy associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. | Q33396969 | ||
| Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial | Q33397004 | ||
| Systemic malignancies as a cause of unexpected microangiopathic hemolytic anemia and thrombocytopenia | Q33397710 | ||
| A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy | Q33397974 | ||
| Factor I autoantibodies in patients with atypical hemolytic uremic syndrome: disease-associated or an epiphenomenon? | Q33399052 | ||
| Complement activation in thrombotic thrombocytopenic purpura | Q33399954 | ||
| Malignant hypertension with reversible brainstem hypertensive encephalopathy and thrombotic microangiopathy | Q33400249 | ||
| Evaluation of clinical outcomes and renal vascular pathology among patients with lupus | Q33400371 | ||
| Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH/CFHR1 hybrid protein | Q33400705 | ||
| An outbreak of Shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children | Q33401628 | ||
| Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study | Q33402456 | ||
| Obstetric nephrology: AKI and thrombotic microangiopathies in pregnancy | Q33402751 | ||
| Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome | Q33402974 | ||
| Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. | Q33403196 | ||
| STEC-HUS, atypical HUS and TTP are all diseases of complement activation | Q33403359 | ||
| Renal and neurological involvement in typical Shiga toxin-associated HUS. | Q33403361 | ||
| Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry | Q33404151 | ||
| Eculizumab treatment of acute antibody-mediated rejection in renal transplantation: case reports | Q33404327 | ||
| Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report. | Q33404622 | ||
| Long-term outcomes of Shiga toxin hemolytic uremic syndrome | Q33405099 | ||
| Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults | Q33405246 | ||
| Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome | Q33405522 | ||
| Changing strategies for organ transplantation in atypical haemolytic uraemic syndrome: a tertiary case series | Q33406251 | ||
| Two patients with history of STEC-HUS, posttransplant recurrence and complement gene mutations | Q33408171 | ||
| Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome | Q33408211 | ||
| Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes | Q33408360 | ||
| Does dysregulated complement activation contribute to haemolytic uraemic syndrome secondary to Streptococcus pneumoniae? | Q33408539 | ||
| Atypical haemolytic uraemic syndrome and pregnancy: outcome with ongoing eculizumab | Q39429501 | ||
| Eculizumab Therapy for Chronic Antibody-Mediated Injury in Kidney Transplant Recipients: A Pilot Randomized Controlled Trial. | Q39512442 | ||
| Systemic complement activation and complement gene analysis in enterohaemorrhagic Escherichia coli-associated paediatric haemolytic uraemic syndrome | Q39758002 | ||
| KDIGO clinical practice guideline for the care of kidney transplant recipients | Q39936865 | ||
| Microangiopathic hemolytic anemia and cancer: a review | Q39961551 | ||
| Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome | Q39983750 | ||
| Rare genetic variants in Shiga toxin-associated haemolytic uraemic syndrome: genetic analysis prior to transplantation is essential | Q40075347 | ||
| Plasma levels of complement C3 is associated with development of hypertension: a longitudinal cohort study | Q40260428 | ||
| Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria | Q40559071 | ||
| Thrombotic microangiopathy and human immunodeficiency virus in the era of eculizumab | Q40593336 | ||
| Factor H Autoantibodies in Patients with Antiphospholipid Syndrome and Thrombosis | Q40639743 | ||
| Rare Variants in the Complement Factor H-Related Protein 5 Gene Contribute to Genetic Susceptibility to IgA Nephropathy | Q40974164 | ||
| Clinical Significance of IgM and C3 Glomerular Deposition in Primary Focal Segmental Glomerulosclerosis | Q41022459 | ||
| A case of relapsing and refractory catastrophic anti-phospholipid syndrome successfully managed with eculizumab, a complement 5 inhibitor | Q41211826 | ||
| Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy | Q41373365 | ||
| Loss of DGKε induces endothelial cell activation and death independently of complement activation | Q41700443 | ||
| Eculizumab Treatment in a Patient with Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy and Steroid-Refractory Acute Graft Versus Host Disease | Q42063587 | ||
| Pathology after eculizumab in dense deposit disease and C3 GN. | Q42116082 | ||
| Renal and neurological response with eculizumab in a patient with transplant associated thrombotic microangiopathy after allogeneic hematopoietic progenitor cell transplantation | Q42200268 | ||
| Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency | Q42256735 | ||
| C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis | Q42274573 | ||
| All Things Complement | Q42386506 | ||
| Eculizumab-induced reversal of dialysis-dependent kidney failure from C3 glomerulonephritis | Q42392710 | ||
| CD46-associated atypical hemolytic uremic syndrome with uncommon course caused by cblC deficiency | Q42400206 | ||
| Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome | Q42674523 | ||
| Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis | Q42963758 | ||
| Use of eculizumab in the treatment of a case of refractory, ADAMTS13-deficient thrombotic thrombocytopenic purpura: additional data and clinical follow-up | Q43078211 | ||
| IgG subclasses and complement pathway in segmental and global membranous nephropathy. | Q43164390 | ||
| Eculizumab as rescue therapy in severe resistant lupus nephritis. | Q43177789 | ||
| Use of eculizumab in crescentic IgA nephropathy: proof of principle and conundrum? | Q43241467 | ||
| Mesangial IgA2 deposits and lectin pathway-mediated complement activation in IgA glomerulonephritis | Q43783224 | ||
| Cellular injury associated with renal thrombotic microangiopathy in human immunodeficiency virus-infected macaques. | Q43862964 | ||
| Complement C5-inhibitor rEV576 (coversin) ameliorates in-vivo effects of antiphospholipid antibodies. | Q43984230 | ||
| Molecular basis for high renal cell sensitivity to the cytotoxic effects of shigatoxin-1: upregulation of globotriaosylceramide expression | Q44111638 | ||
| Meningococcal sepsis complicating eculizumab treatment despite prior vaccination | Q44204666 | ||
| Use of eculizumab in refractory gemcitabine-induced thrombotic microangiopathy | Q44441605 | ||
| Outcome of Plasma Exchange Therapy in Thrombotic Microangiopathy After Renal Transplantation | Q44596912 | ||
| Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria | Q44755395 | ||
| Microangiopathic hemolysis and renal failure in malignant hypertension | Q45185684 | ||
| Anti-C5 as prophylactic therapy in atypical hemolytic uremic syndrome in living-related kidney transplantation | Q45355324 | ||
| Plasmapheresis-resistant acute humoral rejection successfully treated with anti-C5 antibody | Q45736192 | ||
| Complement activation and mortality during an acute episode of thrombotic thrombocytopenic purpura | Q45741802 | ||
| Successful use of eculizumab in a patient with post-transplant thrombotic microangiopathy. | Q45932533 | ||
| Eculizumab for the treatment of preeclampsia/HELLP syndrome | Q46321630 | ||
| Successful treatment of the postpartum atypical hemolytic uremic syndrome with eculizumab | Q46336851 | ||
| Thrombotic microangiopathy as a complication in a patient with focal segmental glomerulosclerosis | Q46991150 | ||
| Hemolytic Uremic Syndrome in Pregnancy and Postpartum | Q47736433 | ||
| Severe hypertension with renal thrombotic microangiopathy: what happened to the usual suspect? | Q49095351 | ||
| The genetics of the alternative pathway of complement in the pathogenesis of HELLP syndrome. | Q49177600 | ||
| Eculizumab Induces Sustained Remission in a Patient With Refractory Primary Catastrophic Antiphospholipid Syndrome | Q50172456 | ||
| Factor H autoantibodies in membranoproliferative glomerulonephritis. | Q50508495 | ||
| Complement factor H mutations are present in ADAMTS13-deficient, ticlopidine-associated thrombotic microangiopathies. | Q51006144 | ||
| Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome | Q33430035 | ||
| Direct evidence of complement activation in HELLP syndrome: A link to atypical hemolytic uremic syndrome | Q33430320 | ||
| Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab | Q33430681 | ||
| Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial | Q33431023 | ||
| Carfilzomib: A cause of drug associated thrombotic microangiopathy | Q33431057 | ||
| Clopidogrel-induced Thrombotic Microangiopathy in a Patient with Hypocomplementemia | Q33431567 | ||
| New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy | Q33432069 | ||
| Pregnancy-related thrombotic microangiopathies: Clues from complement biology | Q33432072 | ||
| The alternative pathway of complement and the thrombotic microangiopathies | Q33432099 | ||
| Proteasome inhibitor associated thrombotic microangiopathy | Q33432949 | ||
| Human mannose-binding lectin inhibitor prevents Shiga toxin-induced renal injury | Q33433630 | ||
| Renal Thrombotic Microangiopathy in Proliferative Lupus Nephritis: Risk Factors and Clinical Outcomes: A Case-Control Study | Q33434207 | ||
| Use of Eculizumab in Atypical Hemolytic Uremic Syndrome, Complicating Systemic Lupus Erythematosus | Q33434807 | ||
| Human neutrophil peptides and complement factor Bb in pathogenesis of acquired thrombotic thrombocytopenic purpura | Q33435545 | ||
| Atypical Hemolytic Uremic Syndrome Secondary to Lupus Nephritis, Responsive to Eculizumab | Q33436295 | ||
| Thrombotic Microangiopathy in Inverted Formin 2-Mediated Renal Disease | Q33437631 | ||
| Micro-angiopathic haemolysis, thrombocytopenia and nephrotic syndrome associated with membranous nephropathy in a Vietnamese boy. | Q33448753 | ||
| Partial H (beta 1H) deficiency and glomerulonephritis in two families | Q33478578 | ||
| Development of focal segmental sclerosis and hyalinosis in hemolytic uremic syndrome | Q33498047 | ||
| Genetic studies into inherited and sporadic hemolytic uremic syndrome | Q33502189 | ||
| Antineutrophilic cytoplasmic antibody-associated vasculitis with hypocomplementemia has a higher incidence of serious organ damage and a poor prognosis | Q33595396 | ||
| Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome | Q33630007 | ||
| Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility | Q33921170 | ||
| Complement factor H autoantibodies are associated with early stage NSCLC. | Q33937882 | ||
| Renal involvement in primary antiphospholipid syndrome: retrospective analysis of 160 patients | Q33944778 | ||
| Role of tissue factor in a mouse model of thrombotic microangiopathy induced by antiphospholipid antibodies | Q34080920 | ||
| Genome-wide association study identifies susceptibility loci for IgA nephropathy | Q34170453 | ||
| Long-term renal outcome in patients with malignant hypertension: a retrospective cohort study. | Q34356666 | ||
| Associations of CFH polymorphisms and CFHR1-CFHR3 deletion with blood pressure and hypertension in Chinese population | Q34359378 | ||
| Characterization of a factor H mutation that perturbs the alternative pathway of complement in a family with membranoproliferative GN. | Q34427591 | ||
| Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice | Q34537391 | ||
| Eculizumab (Alexion). | Q34788815 | ||
| The local complement activation on vascular bed of patients with systemic sclerosis: a hypothesis-generating study | Q35057817 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 600-624 | |
| P577 | publication date | 2017-05-08 | |
| P1433 | published in | Clinical kidney journal / an academic journal of the ERA-EDTA (European Renal Association - European Dialysis and Transplant Association) | Q26842221 |
| P1476 | title | Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea | |
| P478 | volume | 10 |
| Q54262493 | A multicenter experience of thrombotic microangiopathies in Turkey: The Turkish Hematology Research and Education Group (ThREG)-TMA01 study. |
| Q96304889 | An update on the management of antiphospholipid syndrome |
| Q92766925 | Complement-mediated microangiopathy in IgA nephropathy and IgA vasculitis with nephritis |
| Q92675561 | Dengue virus and the complement alternative pathway |
| Q48256943 | Diseases of complement dysregulation-an overview |
| Q90618941 | Haemolytic uremic syndrome: diagnosis and management |
| Q61651844 | Hyperfunctional complement C3 promotes C5-dependent atypical hemolytic uremic syndrome in mice |
| Q58788522 | TTP-like syndrome: novel concept and molecular pathogenesis of endotheliopathy-associated vascular microthrombotic disease |
| Q64993828 | Targeting properdin in the treatment of atypical haemolytic uraemic syndrome: better than eculizumab? |
| Q91811163 | The Use of Tick Salivary Proteins as Novel Therapeutics |
| Q61799225 | The new , 4 years later |
| Q50085453 | Thrombotic Microangiopathy and the Kidney |
| Q52728783 | What is the evidence for the role of therapeutic apheresis in the management of complement-associated thrombotic microangiopathies? |
Search more.